Global Cord Blood Corporation Announced Cellenkos Receives FDA Clearance of IND Application for CK0804 as Add on Therapy to Ruxolitinib for the Treatment of Myelofibrosis ...Middle East

HONG KONG, June 16, 2022 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, is pleased to announce that Cellenkos, Inc....

Hence then, the article about global cord blood corporation announced cellenkos receives fda clearance of ind application for ck0804 as add on therapy to ruxolitinib for the treatment of myelofibrosis was published today ( Thursday 16/06/2022 - 11:44 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Global Cord Blood Corporation Announced Cellenkos Receives FDA Clearance of IND Application for CK0804 as Add on Therapy to Ruxolitinib for the Treatment of Myelofibrosis )

Also on site :

• European ‘propaganda’ using Russia as ‘external enemy’ to mask crises – Kremlin
• What’s known about the man charged with attempting to assassinate President Trump at the White House Correspondents’ Dinner
• We can make sure another Chornobyl disaster does not happen, here is how